Skip to Content

Tafinlar Dosage

Generic name: DABRAFENIB MESYLATE 50mg
Dosage form: capsule

Medically reviewed on May 4, 2018.

Patient Selection

Melanoma

  • Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR as a single agent [see Warnings and Precautions (5.2) and Clinical Studies (14.1)].
  • Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see Warnings and Precautions (5.2), Clinical Studies (14.2), (14.3)].
  • Information on FDA-approved tests for the detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.

NSCLC

  • Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see Clinical Studies (14.4)].
  • Information on FDA-approved tests for the detection of BRAF V600E mutations in NSCLC is available at: http://www.fda.gov/CompanionDiagnostics.

ATC

  • Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with TAFINLAR and trametinib [see Clinical Studies (14.5)].

Recommended Dosage for Unresectable or Metastatic Melanoma

The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, as a single agent or in combination with trametinib, until disease progression or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information.

Recommended Dosage for the Adjuvant Treatment of Melanoma

The recommended dosage of TAFINLAR is 150 mg orally taken twice daily in combination with trametinib until disease recurrence or unacceptable toxicity for up to 1 year. Refer to the trametinib prescribing information for recommended trametinib dosing information.

Recommended Dosage for NSCLC

The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, in combination with trametinib until disease recurrence or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information.

Recommended Dosage for ATC

The recommended dosage of TAFINLAR is 150 mg orally taken twice daily, in combination with trametinib until disease recurrence or unacceptable toxicity. Refer to the trametinib prescribing information for recommended trametinib dosing information.

Administration

  • Take TAFINLAR at doses approximately 12 hours apart.
  • Take TAFINLAR at least 1 hour before or 2 hours after a meal [see Clinical Pharmacology (12.3)].
  • Do not take a missed dose of TAFINLAR within 6 hours of the next dose of TAFINLAR.
  • Do not open, crush, or break TAFINLAR capsules.

Dosage Modifications for Adverse Reactions

Dose reductions for adverse reactions associated with TAFINLAR are presented in Table 1.

Table 1. Recommended Dose Reductions for TAFINLAR for Adverse Reactions
Action Recommended Dose
First Dose Reduction 100 mg orally twice daily
Second Dose Reduction 75 mg orally twice daily
Third Dose Reduction 50 mg orally twice daily
Subsequent Modification Permanently discontinue if unable to tolerate TAFINLAR 50 mg orally twice daily

Dosage modifications for adverse reactions associated with TAFINLAR are presented in Table 2.

Table 2. Recommended Dosage Modifications for TAFINLAR for Adverse Reactions
aNational Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0.
bSee Table 1 for recommended dose reductions of TAFINLAR.
cDose modifications are not recommended for TAFINLAR when administered with trametinib for the following adverse reactions of trametinib: retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), interstitial lung disease/pneumonitis, and uncomplicated venous thromboembolism. Dose modification of TAFINLAR is not required for new primary cutaneous malignancies.
Severity of Adverse Reactiona Dose Modification for TAFINLARb
New Primary Malignancies
Non-Cutaneous RAS Mutation-positive Malignancies Permanently discontinue TAFINLAR.
Cardiac
  • Symptomatic congestive heart failure
  • Absolute decrease in LVEF of greater than 20% from baseline that is below LLN
Withhold TAFINLAR, if improved, then resume at the same dose.
Uveitis
  • Uveitis including iritis and iridocyclitis
If mild or moderate uveitis does not respond to ocular therapy, or for severe uveitis, withhold TAFINLAR for up to 6 weeks.
  • If improved to Grade 0-1, then resume at the same or at a lower dose level.
  • If not improved, permanently discontinue.
Febrile Drug Reaction
  • Fever of 101.3°F to 104°F
Withhold TAFINLAR until fever resolves. Then resume at same or lower dose level.
  • Fever higher than 104°F
  • Fever complicated by rigors, hypotension, dehydration, or renal failure
  • Withhold TAFINLAR until fever resolves. Then resume at a lower dose level.
Or
  • Permanently discontinue TAFINLAR.
Dermatologic
  • Intolerable Grade 2
  • Grade 3 or 4
Withhold TAFINLAR for up to 3 weeks.
  • If improved, resume at a lower dose level.
  • If not improved, permanently discontinue.
Other Adverse Reactionsc
  • Intolerable Grade 2
  • Any Grade 3
Withhold TAFINLAR.
  • If improved to Grade 0-1, resume at a lower dose level.
  • If not improved, permanently discontinue.
  • First occurrence of any Grade 4
  • Withhold TAFINLAR until adverse reaction improves to Grade 0-1. Then resume at a lower dose level.
Or
  • Permanently discontinue TAFINLAR.
  • Recurrent Grade 4
Permanently discontinue TAFINLAR.

Refer to the trametinib prescribing information for dose modifications for adverse reactions associated with trametinib.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide